BLENREP^®

(belantamab mafodotin) 
GLAXOSMITHKLINE 
HK Reg. No. HK-69000, HK-69001 (02 Mar, 2026)   

Composition⁴:
BLENREP^® is available as:

• 70 mg powder for concentrate for solution for infusion

• 100 mg powder for concentrate for solution for infusion

Indication⁴:
BLENREP^® is indicated in adults for the treatment of relapsed or refractory multiple myeloma:

•In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
•In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide

References

 4. EMA. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf. [Accessed 12 March 2026].